Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.56 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12764158 | 0.86 | RAB9A (0.68) | GAAMAPK1LMNAPOLBL3MBTL1 | |
| SCHEMBL4191155 | 0.82 | GAA (0.62) | GAAMAPK1LMNAPOLBL3MBTL1 | |
| SCHEMBL11984234 | 0.81 | GAA (0.57) | GAAMAPK1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL13616127 | 0.79 | NAMPT (0.71) | GAAMAPK1LMNAPOLBL3MBTL1 | |
| SCHEMBL31524185 | 0.79 | GAA (0.62) | GAAMAPK1LMNAPOLBL3MBTL1 | |
| SCHEMBL28025774 | 0.78 | NPC1 (0.64) | POLBSMN1; SMN2KCNK3KCNK9RAB9A | |
| SCHEMBL17465718 | 0.78 | NPC1 (0.64) | LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL19242053 | 0.78 | GAA (1.00) | GAAMAPK1LMNAPOLBL3MBTL1 | |
| SCHEMBL4016790 | 0.78 | KMT2A (0.52) | LMNASMN1; SMN2BLMHTTBRAF | |
| SCHEMBL19479148 | 0.78 | KCNQ3 (0.50) | MAPK1LMNASMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | GAA 1096/4885MAPK1 246/4885LMNA 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.